However, controversies aside, the cannabis industry is creating some interesting opportunities for investors. More businesses are developing medical and consumer healthcare products using the young commodity. And consequently, market forecasts indicate potentially explosive growth over the next decade.

With that in mind, let’s dive into the world of UK cannabis stocks and see which businesses are leading the charge.

What are cannabis stocks?

As the name implies, cannabis stocks consist of any business using marijuana to create a legal product for other companies or consumers. The sector is still in its infancy, but it can be broken down into three primary categories:

• Growers & Retailers – Companies creating consumer products with cannabis.
• Medical – Pharmaceutical and biotech firms are creating medicinal marijuana products for patients.
• Ancillary – Groups providing products or services to other cannabis companies.

As such, there are a vast number of products coming out of this young industry, including food, beverages, lotions, oils, perfume, and medicine, just to name a few.

Typically, a commodity with this many applications doesn’t create a high barrier to entry. However, in the case of marijuana shares, the story is quite different. The regulatory environment surrounding cannabis in most nations is unsurprisingly strict. And the UK is no exception.

Most cannabis-based products require regulatory approval before they can be sold to consumers. And in the case of UK medical marijuana firms, additional authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) is also necessary, which can be both time-consuming and expensive.

Needless to say, this does elevate the risk profile. And subsequently, cannabis shares are often synonymous with volatility. But there are also stories of immense growth potential, so the risk does come with potentially higher rewards for investors.

Top marijuana shares in the UK

Many cannabis has struggled to penetrate their markets, resulting in most failing, relisting in other markets, or returning to the private markets. However, as of February 2026, a few remain on the London Stock Exchange:

Associated British Foods

Associated British Foods is not the most well-known cannabis stock. After all, this is the company behind many popular food brands, including Kingsmill bread and Blue Dragon cooking sauces. It’s also the parent company of clothing retailer Primark.

However, in 2017, the group’s subsidiary, British Sugar, signed a deal with GW Pharmaceuticals (now owned by Jazz Pharmaceuticals) to supply M250 marijuana for drug development purposes. M250 contains high concentrations of the active ingredient cannabidiol without producing a psychoactive effect. In other words, the plants can’t be harvested for recreational marijuana purposes.

Subsequently, Associated British Foods converted around 45 acres of tomato greenhouse space to grow hemp plants, making it one of the largest licensed cultivators in the UK.

Futura Medical

Futura Medical is an early-stage research and development pharmaceutical company. The group focuses on novel treatments aimed at sexual health and pain relief using its proprietary DermaSys technology.

This enables active pharmaceutical ingredients to be formulated into a gel absorbed directly through the skin. As such, it’s a highly targeted solution that’s proving to be successful with its flagship MED3000 erectile dysfunction treatment and its TPR100 non-steroidal anti-inflammatory treatment.

However, as it turns out, DermaSys is entirely compatible with cannabidiol. And the company has since begun developing a new gel called CBD100 in a joint venture with CBDerma Technology. While it’s still in the early stages of development, initial lab testing showed promising results for this future cannabis stock.

Consequently, management has begun exploring commercialisation options for new cosmetic, dermal, and pain relief treatments using cannabidiol as the primary ingredient.

Investing in the United States’ marijuana industry

American cannabis stocks have to navigate a more complex regulatory environment. Currently, 40 states have legalised marijuana for medical use, with 24 allowing for recreational purposes as well. However, on a federal level, it remains a controlled substance, which significantly limits the geographic expansion of these businesses.

In April 2022, the US House of Representatives passed a new bill to legalise cannabis on a federal level. However, it ultimately failed to pass the Senate.

As such, the prospects for Federal legalisation of cannabis remain distant. However, in 2022, the US government began making moves to reclassify the drug from Schedule I to Schedule III – a significant but still incremental development.

Some leading American cannabis stocks in order of market cap as of February 2026 are:

1. Jazz Pharmaceuticals (NASDAQ:JAZZ) – $10.5bn
2. Scotts Miracle-Gro (NYSE:SMG) – $4.0bn
3. Innovative Industrial Properties (NYSE:IIPR) – $1.3bn
4. GrowGeneration (NASDAQ:GRWG) – $64.6m
5. Hydrofarm Holdings Group (NASDAQ:HYFM) – $6.2m

Are cannabis shares right for you?

Just looking at these five cannabis stocks, an investor who bought equal positions in each over the last five years is probably quite disappointed. That’s because collectively, these shares have fallen drastically.

Seeing such poor performance from an unproven industry isn’t exactly surprising. And demonstrates the risks of being an early investor. That’s why investing in marijuana stocks is not suitable for everyone.

Having said that, industry forecasts predict enormous growth over the next decade. If these prove to be accurate, the cannabis market could be an explosive opportunity for risk-seeking investors.

We recommend taking a diversified approach. It’s pretty challenging to determine which companies will become future titans at this stage. And by owning a collection of promising businesses, the odds of finding a winner increase.

The post Top UK Cannabis Stocks of 2026 appeared first on The Motley Fool UK.

I think this represents an opportunity for long-term investors like me to nip in and grab some bargains. Here are two top penny stocks I think could deliver exceptional returns in the years ahead.

Steppe one for big returns

The tragic events unfolding in Eastern Europe has prompted some heavy selling of Steppe Cement (LSE: STCM) shares recently. The building product manufacturer operates neither out of Russia nor Ukraine. But the Kazakhstan-focused business could still be affected by economic and political spillover stemming from the war.

Steppe Cement’s share price recently ducked to its cheapest since autumn 2020. And this leaves the business trading on a forward P/E ratio of 3.9 times. It’s true that Kazakhstan’s economy could be indirectly hit by the sanctions that are being slapped on neighbour Russia. But as a long-term investor I believe the outlook for this penny stock remains compelling. And at current prices I think it’s a steal.

You see, I expect demand for Steppe Cement’s product to increase as levels of urbanisation rise sharply in Kazakhstan. Currently around 58% of the country’s population lives in cities, a number that its government aims to lift to 70% by 2050. Massive investment in building homes, infrastructure and utilities will be needed in the coming decades to make this target a reality.

Should I buy before a possible rebound?

A shortage of news on its MED3000 erectile dysfunction gel hasn’t helped the Futura Medical (LSE: FUM) share price. 2021 was a big year for the company as it received approval to begin clinically trialling its product in the gigantic US marketplace. It also received a CE mark from European regulators that could fast-track the gel’s rollout internationally. And Futura inked a series of agreements with licensing partners too.

It’s perhaps understandable that investor interest in Futura Medical has waned in the absence of fresh news. As a long-term investor, though, I’m thinking of using recent weakness as an opportunity to buy. Its fast-acting gel — which can be sold without the need for a doctor’s prescription — could be a game-changer in the rapidly-growing erectile dysfunction market.

Futura’s latest market update in December announced the commencement of six-month trials of MED3000 in the US. Obviously disappointing results during the trials could have a disastrous impact on the company’s share price. But this is a risk I might be willing to take given the scale of recent share price weakness (Futura has fallen more than a third in value since the start of 2022).

The post £500 to invest? 2 falling penny stocks to buy right now appeared first on The Motley Fool UK.

As a long-term investor, however, Revolution Bars is a share that’s still drawing my attention. The business operates dozens of premium bars across the country. It’s therefore well placed to exploit the trend of consumers spending ever-higher proportions of their income on going out. Leisure spending in Britain has been growing at twice the rate of retail in recent times.

Most recent trading data from Revolution Bars has illustrated the robustness of this trend too. Between 19 July and 2 October the business saw sales jump 17% compared with the same period two years earlier.

A rare beauty

I also like Rainbow Rare Earths (LSE: RBW). Demand for rare earth metals has rocketed over the past decade as the manufacture of mobile phones, computers and other consumer electronics has boomed. Elements like neodymium and praseodymium (commonly known as NdPr) are essential components in making such hi-tech devices run. Some analysts think that demand growth will move up several notches too as the green technology revolution kicks off.

Take the boffins at investment firm CITIC, for example. They’re predicting that “downstream demand for rare earths is expected to continue to improve” as sales of low-emission cars, wind turbines and special energy-saving air conditioners rise. At the same time CITIC thinks supply from China, the world’s largest supplier of rare earths, will fall as local lawmakers clamp down on unregulated production.

All this bodes well for NdPr prices for the first part of the decade, and by extension profits at Rainbow Rare Earth. Through its Gakara project in Burundi the company is sitting on one of the richest rare earths resources on the planet. Mining is a notoriously difficult business and setbacks can deal a significant blow to profits. However, I think predictions of soaring demand still make this penny stock very attractive today.

A penny stock for 2022 and beyond?

I think Futura Medical could be on the cusp of delivering explosive revenues growth. In a potentially game-changing year, the business — which has high hopes for its MED3000 erectile dysfunction gel — has received the green light to begin trials in the US. And it now has the critical ‘CE’ marking in European markets, as well as having signed key licensing agreements spanning the globe.

Futura has a battle on its hands to take on Pfizer’s market giant Viagra. But the fast-acting nature of its product could still make it a winner in a rapidly-growing market. That’s providing trials of MED3000 yield positive results in 2022. It’s estimated that global impotence rates will have doubled between 1995 and 2025.

The post £1,000 to spend? 3 penny stocks to buy today appeared first on The Motley Fool UK.

Now all three have released updates. I think this is a good time to take a closer look at their performance.

Deliveroo expects growth slowdown

Deliveroo has delivered impressive growth in the past year, partly due to the lockdown. This continues into the first quarter of the year. Its orders have risen by 114% from the year before. Its gross transaction value (GTV), which is the total value paid by customers, net of discounts and discretionary tips, rose by 130%. 

The challenge though, is that Deliveroo does not expect this growth to continue. It expects GTV growth to be between 30% and 40% for the year, unchanged from estimates mentioned in its prospectus. 

While it is undeniable that this is a sharp come-off, even at the forecast levels, growth is still quite strong. The company delivers in 50 cities worldwide, which increases the scope of its future expansion too. While it has been in a weak place since it started trading, I reckon that as and when its issues get resolved, investors will look more positively at the UK share. 

Volex gets a boost from electric vehicles

The power cord and cable assembly supplier, Volex, just reported a huge increase in demand from electric vehicles (EV) customers. It was an increase of 187% for the year ending 4 April, 2021. 

As a percentage of total revenues, those from EV-related sales are still small at 12%, however. But going by the policy push for the segment and increased consumer interest as well, I reckon it can drive growth for the company going forward. 

Volex has already seen a share price doubling in less than a year, though. And going by the price-to-earnings (P/E) ratio at 36 times, it is pricey too. But then again, in the current markets many stocks have become pricey. And I reckon this stock market rally will continue, which makes this UK share at least one to consider for me. 

Futura Medical share price stays elevated

Pharmaceutical company Futura Medical recently saw a sharp upturn in share price. It was driven by approval from the US authorities to conduct clinical trials for its erectile dysfunction treatment. It has also recently come closer to receiving an approval from the EU for over-the-counter sale of the product. 

The second approval would start generating revenues for Futura Medical, which so far has none. It has reported a narrowing of losses in its latest annual results though, as expenses fell. 

There has been little share price movement for the stock since. It has fallen from the heights it suddenly rose to as approval from the US happened. But it is still way above the levels it was trading at before the news came in. I think this is a UK share to look out for, though I am not buying now. 

The post Would I buy the Deliveroo, Volex, and Futura Medical shares now? appeared first on The Motley Fool UK.

Penny stocks often overlooked

I believe penny stocks are often overlooked as risky investments. After all, they are priced low for a reason. However, I believe some penny stocks could lead to some excellent returns.

The Futura Medical share price has risen sharply in the last week. Futura is a pharmaceutical research and development firm with a focus on topical formulations and transdermal delivery. In simpler terms, it is medication that is used by applying it to the skin. To date, its largest achievement is its proprietary DermaSys transdermal technology. As with many smaller firms, it relies on commercial partnerships.

Futura Medical share price

The past seven days have been a whirlwind for Futura. The reason behind it’s share price rise is been a breakthrough in an agreement between itself and the US Food and Drug Administration (FDA). A clinical study into Futura’s erectile dysfunction treatment (known as MED3000) will now be conducted. This is a step closer to the treatment receiving regulatory approval in the US, which could be fruitful.

The Futura Medical share price has also benefited from an approval by an EU body last week too. This could see MED3000 sold over the counter in the region. The good news linked to the EU approval is that fast-track reviews could occur in the Middle East, Africa, and Latin America.

As I write this, shares in Futura are trading for over 50p per share. Last week, it was trading for just 18p per share. A year ago today, it was trading for less than 10p per share. I believe this goes to show how big this latest breakthrough is for Futura.

Is Futura worth the risk?

Futura has other products and technology too, which could boost future performance and share price. It is working on its own anti-inflammatory gel labelled TPR100, which is awaiting regulatory authorisation in the UK. It has also joined the cannabis-based medicines race that has recently attracted a lot of headlines and interest.

Despite the recent breakthrough and optimism there are very real risks involved with Futura as a penny stock. The past two years have seen very little revenue reported. It is currently also loss-making, which is expected for smaller pharma firms at this stage in their journey. Although expected, I am not buoyed by this.

I am not willing to risk my hard-earned cash on the Futura Medical share price just now. I will keep a keen eye on developments, however. Regulatory approvals and distribution could change things. There are plenty of penny stocks that are established and profit making which I much prefer.

The post Futura Medical share price: a penny stock rising fast right now appeared first on The Motley Fool UK.

What’s the story?

Future Medical is a UK-based pharmaceutical company that focuses on the development of products through R&D. It then looks to partner with other businesses to take the product from late stage development to the market. 

It has taken an erectile dysfunction product to commercialisation stage in the past, but the main news at the moment surrounds products that are still in development. These include products with handy names such as MED3000 and TPR100. These are both types of gels, used for different purposes.

In recent news, MED3000 gained EU approval to go on sale. This was very positive news, and the CE mark also makes it easier to be fast-tracked through trial processes around the world. This was followed up by news that the same product is undergoing FDA studies as well.

For Futura Medical shares, the news saw a sharp move higher. This is logical, given the the main way Futura Medical has value as a company is via getting its products past research stage and onto shelves for sale. Until then, Futura Medical shares are fuelled a lot on speculation of what could happen. 

Should I buy Futura Medical shares?

Even with the approval, I still think Futura Medical shares should be treated carefully. After looking through recent results, it’s clear that the costs of development really do rack up. The latest results for H1 2020 showed research costs of £926k, with revenue at £0. That’s correct — the business didn’t generate a penny of revenue in that period.

Even during the whole of 2019, revenue stood at just over £31k against research costs of over £10m. It doesn’t take a genius to compute that this is a loss making business. For Futura Medical shares to trade at current levels reflects a market valuation of £125m. I find this quite surprising.

Of course, I do understand that Futura Medical shares are pricing-in future potential. This is a viable investing strategy and can yield very high results. But this feels like I’m investing in a start-up business that’s trying to get off the ground. That’s not the type of investment I’m looking for. I’d prefer to buy into companies that have established track records.

Futura Medical shares could build on the 200% rally, and move even higher on future approvals and commercialisation of products. If the business establishes itself as a viable player in this regard, I’ll happily look to invest then. But at this stage of the life-cycle, it’s just too risky for me to justify buying.

The post Futura Medical shares are up 200% in a week! Here’s what I need to know appeared first on The Motley Fool UK.

This sounds promising. However, I do think it is important to figure out if the news is as good as it sounds on the surface. And following from there, if the company can sustain its share price increase. 

Regulatory progress 

The impetus for the share price increase was an agreement between the US Food and Drug Administration and Futura Medical. A clinical study of its erectile dysfunction treatment (MED3000) has to now be conducted. This is one step forward for the company in obtaining regulatory approval from the country.

This release follows a recommendation for approval by an EU body last week. This would allow MED3000 to be sold over-the-counter in the region. An EU approval will allow fast-track reviews in countries in the Middle East, Africa and Latin America. It could then become quickly available in these countries too. 

Capturing market share

Futura Medical’s treatment targets a treatment with growing demand. It is estimated that the erectile dysfunction drugs market will grow at a compounded annual rate of 5% between 2019 and 2026. 

I think this suggests that MED3000 could capture some of the market share of the growing segment, especially as Pfizer’s Viagra patent ended in 2020. This gives more pharmaceutical companies an opportunity to bring in their own version of erectile dysfunction treatments. 

At the same time, it also means more competition. In other words, MED3000 may or may not succeed, like any other Viagra substitute that is entering the market. 

Cannabis-based treatments

But Futura Medical has other treatments in the pipeline too. One of these is TPR100, an anti-inflammatory gel. It has conducted clinical studies and is currently awaiting regulatory authorisation in the UK. 

Interestingly, it is also developing cannabis-based treatments. Medical cannabis companies have recently started listing on the London Stock Exchange to much investor interest. In a joint venture with CBDerma Technology, the AIM-listed company will bring in its patented technology, DermaSys, for CBD treatment delivery through skin. 

No revenues

Futura Medical’s products and technology sound promising, but I think it is important to keep in mind that its revenues have been erratic over time. In the last two full years for which financial information is available – 2018 and 2019 – the company reported little by way of revenue. 

While things can change in the future, it does indicate that we do not know how they will turn out. Besides, it is loss-making too, as would be expected. 

What I’d do now

I think the stock has potential but it is also high risk, especially after the sudden and sharp rise in its share price. I reckon it will come off from here so I would not like to consider buying it now. As and when it gets the approvals for distribution for MED3000, I will take a look at the Futura Medical share again. 

The post What I’d do after the Futura Medical share price rose 65% today  appeared first on The Motley Fool UK.

Once the certification comes through, it means the topical gel can be purchased over the counter without a prescription. MED3000 gel is an erectile dysfunction treatment. Futura Medical expects full approval by the end of May, with EU certification and the subsequent CE mark.

This is a significant breakthrough for the company, as it will be the first of its kind available in Europe. And it lays the foundations for global approval. In the meantime, the company is also seeking marketing approval for MED3000 in the US. Again, this will be for use as a non-prescription, over-the-counter treatment.

A penny share with room for growth

Futura Medical is a penny share and as such carries considerable risk to shareholder capital. The company’s profitability depends on sales. While the treatment for approval is undoubtedly a positive step in the right direction, it still has to complete a clinical trial for a supplementary study.

The company projected the market for this product to be worth around $5.6bn, which is a significant sum. And there is clearly scope for a considerable share price upside—if the company can get its product to market and achieve a high level of sales.

Erectile dysfunction is a condition affecting one in five men globally. And being of a sensitive nature, means over-the-counter treatments could well be favoured over prescription only options.

James Barder, CEO of Futura, commented: “Once the certificate is issued, MED3000 may be marketed throughout the EU without the need of a doctor’s prescription subject to any national marketing restrictions. This will represent a significant commercial opportunity.”

Some analysts also believe MED3000 gel could be a safer and preferable alternative to prescription only rival products such as Viagra, Cialis, and Levitra. Earlier this month the company signed a deal with private equity firm Co-High to help it roll out MED3000 throughout China and South East Asia. Co-High will also cover Futura’s development and approval costs, which are expected to be around £4m. Futura will then earn 50% of any profits realised. 

Developing cannabidiol gel

This is not the only product the company is working on. Last summer it announced successful studies on a cannabidiol gel, called CBD100, which is intended to be used for several applications and indications expected to range from cosmeceutical through to pharmaceutical dermal and pain relief treatments. The company hopes to produce a high-quality cannabidiol gel that’s superior to unregulated, low-tech products in circulation.

Futura Medical financials

Futura Medical has a £99m market capitalisation, earnings per share are negative, and it doesn’t offer a dividend. Its share price has seen extreme volatility over the years.

The Futura Medical share price is now sitting around 40p, which has more than doubled overnight. But this remains far below its 2016 high of 95p.

The company is developing products in highly lucrative markets, with lots of potential for growth. However, I’m not tempted to buy Futura Medical shares today as it’s too speculative an investment for me at this time. Personally, I prefer a well-established healthcare stock such as AstraZeneca as a long-term investment.

The post Penny share in focus: why did the Futura Medical share price soar 125%+ today? appeared first on The Motley Fool UK.

An attractive income play

Shares in Kier Group (LSE: KIW) were hammered by Brexit fallout last year, but they’ve since come bouncing back. At 1,466p, the price has soared by 57% since 2016’s low point in early July, and we’ve seen an overall 13% gain over the past 12 months — as if the turmoil never even happened.

Short-term panic soon gives way to rational judgment, and in the case of this building and civil engineering contractor, the fundamentals are looking good — and I reckon we’re looking at a nice long-term cash cow here.

The first half of the current year brought in a 12% rise in underlying pre-tax profit, with earnings per share up 11%, and the interim dividend was lifted by 5% to 22.5p per share. A similar rise in the final dividend would provide a full-year yield of 4.6%, which looks set to be well covered by dividends and seems safe to me.

The firm enjoys good visibility over future work too — in the words of chief executive Haydn Mursell, Kier is “encouraged by the pipeline in the Property and Residential businesses and our healthy order books of approximately £9bn in the Construction and Services businesses“.

Forecasts put Kier shares on P/E multiples of 12 to 13 or so for the next two years. Net debt of £179m might dent the attractiveness of that a little, but at 1 x EBITDA I don’t see it as a problem. No, I see Kier shares as still good value despite their recent gains, and I expect a healthy stream of future dividends.

Growth star in the making?

Turning to the growth front, Futura Medical (LSE: FUM) is a possible pharmaceuticals and biotechnology winner with interesting prospects.

It’s big in the field of erectile dysfunction with its Eroxon candidate having “the potential to be the world’s fastest-acting treatment for ED“, and its aspirations are supported by a “novel erectogenic condom“. Oh, and it does pain-relief stuff too.

The erectile dysfunction gel is certainly good at getting the share price up — it caused a surge back in September 2016 when Futura announced “breakthrough results” from early trials and spoke of a potential $5bn market. Thursday’s full-year update continued the enthusiasm, telling us the firm intends to “begin a Phase III placebo-controlled parallel group multi-centre clinical study of 700 or more patients in Q4 2017″.

An investment in a company like this, which is not generating profits yet, is definitely not to be undertaken lightly. Indeed, far from a profit, Futura recorded a net loss of £3.7m for the year — though that is down from 2015’s loss of £5.08m, thanks to lower spending on clinical trials.

On the bright side, a share placing in November raised £12m for the coffers, and at 31 December the company had cash resources of £12.35m.

That looks like a reasonably healthy position to me at this stage in the company’s development, but medical progress can be painfully slow and we really can’t tell how long it will be (assuming a successful Phase III and eventual clinical approval) before sales start ramping up enough to achieve profits.

So Futura Medical is still a risky investment, but if you can live with that I’d say it’s one of the more promising of its kind that I’ve seen recently.

The post 2 stocks with great dividend and growth potential appeared first on The Motley Fool UK.

Wide margin of safety

Certainly, BHP has an excellent track record of delivering improved productivity in its coal business, with the division having recorded $3bn in productivity gains in the last four years. Furthermore, BHP is targeting an additional $600m in productivity gains by the end of the 2017 financial year and this looks set to have a positive impact on its bottom line.

In fact, BHP is expected to increase its earnings by 179% in the next financial year and this puts its shares on a price-to-earnings growth (PEG) ratio of just 0.2. While volatility may be high and BHP remains a risky stock to own, its low valuation indicates that it has a sufficiently wide margin of safety for investors to buy for the long term.

Also reporting today was NWF Group (LSE: NWF), the specialist agricultural and distribution business, which announced that its performance in the year to 31 May was in-line with expectations. Notably, it made progress in terms of strategic development, with three acquisitions performing well following successful integration into NWF.

Well-diversified business

Although market conditions are challenging, NWF continues to invest for future growth and its cash generation remains strong. This has allowed it to conduct a major capital expenditure programme which could help to boost profitability in the long run.

With NWF expected to increase its earnings by 6% in the current year and its shares trading on a price-to-earnings (P/E) ratio of only 11.4, it seems to offer good value for money. Certainly, its financial performance could disappoint over the medium term, but with a wide margin of safety and a well diversified business NWF has a relatively appealing risk/reward ratio at the present time.

Meanwhile, shares in Futura Medical (LSE: FUM) have soared by 13% today after the release of its AGM statement. In a very positive update, Futura said that it is pleased with the recent progress in the commercialisation of its pipeline.

Clear potential for value generation

The company is preparing for the commercial launch of new products, as well as being in discussions with regulatory authorities regarding manufacturing sites. And with interest being received following Futura’s positive clinical data announced last year, it believes there is clear potential for value generation in this year and beyond.

Of course, Futura remains a relatively high risk play and with it due to remain loss-making in each of the next two years, its shares could fail to maintain today’s strong gains. As such, and while it has a bright long term future, it may only be of interest to less risk averse investors.

The post Do today’s updates from BHP Billiton plc, NWF Group plc and Futura Medical plc make them star buys? appeared first on The Motley Fool UK.